文献速递认知障碍与痴呆

高教育程度与阿尔茨海默病中加速的tau积累相关

Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease.
PubMed 文献 · JAMA Neurol · 2025-07-07

该队列研究纳入ADNI、A4和GHABS三个独立样本共887名参与者,发现淀粉样蛋白阴性组中高教育程度者tau积累较慢,而淀粉样蛋白阳性组中高教育程度与加速的tau积累和扩散相关。靶向淀粉样蛋白治疗可能减轻高教育程度AD患者中血浆p-tau217相关的tau积累。

要点

  • 淀粉样蛋白阴性时,高教育程度者tau积累更慢。
  • 淀粉样蛋白阳性时,高教育程度与tau加速积累和扩散相关。
  • 靶向淀粉样蛋白治疗或可减轻高教育程度者的tau进展。

核心结论

  • 高教育程度在淀粉样蛋白阳性个体中与更快的tau积累和扩散相关,凸显淀粉样蛋白清除对高教育程度AD患者减缓tau进展的重要性。

研究设计与样本

  • ADNI和GHABS分别代表北美和中国南方人群,A4为多中心试验。
  • 纳入有淀粉样蛋白β和后续tau PET数据的参与者,部分有血浆p-tau217和静息态功能磁共振数据。
  • 数据分析时间为2022年7月至2025年1月。

关键数值与推荐

  • 高教育程度与低教育程度按教育年限中位数分类。
  • 在淀粉样蛋白阳性个体中评估教育状态与淀粉样蛋白负荷、内嗅皮层tau和血浆p-tau217对tau积累的交互作用。

临床怎么用

  • 对淀粉样蛋白阳性且教育程度高的AD患者,应重视淀粉样蛋白清除以减缓tau进展。
  • 靶向淀粉样蛋白治疗可能对此类患者中血浆p-tau217相关的tau积累具有减轻作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The impact of educational attainment (EA) on longitudinal tau accumulation remains largely underexplored. OBJECTIVE: To investigate the association of EA with tau accumulation in Alzheimer disease (AD). DESIGN, SETTING, AND PARTICIPANTS: This cohort study used 3 independent samples: the Alzheimer's Disease Neuroimaging Initiative (ADNI; October 2015-July 2022, mean follow-up: 3.0 years), Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease study (A4; 2014-2022, mean follow-up: 4.7 years), and Greater-Bay-Area Healthy Aging Brain Study (GHABS; July 2021-August 2024, mean interval from plasma collection to tau positron emission tomography [PET]: 1.0 years). The ADNI and GHABS represent Northern American and Southern Chinese populations, respectively. A4 is a multicenter trial. Participants with amyloid β (Aβ) and subsequent tau PET were included from ADNI, A4, and GHABS, and a subset had plasma phosphorylated tau (p-tau) 217 (p-tau217) and resting-state functional magnetic resonance imaging (RS-fMRI) data. Data were analyzed from July 2022 to January 2025. EXPOSURES: EA, Aβ-PET, tau-PET, plasma p-tau217, and RS-fMRI. MAIN OUTCOMES AND MEASURES: Participants were classified as high EA and low EA based on median years of EA. Longitudinal tau changes were compared across Aβ-PET positivity and EA groups. Interactions of EA status with Aβ burden, entorhinal tau, and plasma p-tau217 on tau accumulation were investigated in Aβ-positive (Aβ+) individuals. Connectivity-associated tau spread was compared across different Aβ/EA groups. Whether or not Aβ-targeting treatment attenuated tau accumulation in Aβ+ high-EA individuals was also evaluated. RESULTS: This study included 887 participants: 377 from ADNI (mean [SD] age, 73.3 [7.2] years; 191 female [50.7%]), 395 from A4 (mean [SD] age, 71.9 [4.8] years; 223 female [56.5%]), and 115 from GHABS (mean [SD] years, 66.0 [7.4] years; 76 female [66.1%]). In the Aβ-negative group, high-EA individuals exhibited slower tau accumulation than low-EA individuals (right middle temporal gyrus: estimate = -0.002; 95% CI, -0.003 to -0.0002; P = .03). Conversely, higher EA in the Aβ+ group was correlated with accelerated tau accumulation (left middle temporal gyrus: estimate = 0.003; 95% CI, 0.0003-0.005; P = .03) and stronger Aβ-associated (left visual region: estimate = 0.38; 95% CI, 0.11-0.65; P = .006), entorhinal tau-associated (left middle temporal gyrus: estimate = 0.35; 95% CI, 0.08-0.63; P = .01), and plasma p-tau217-associated tau accumulation (left inferior temporal gyrus: estimate = 0.46; 95% CI, 0.02-0.90; P = .04), as well as increased connectivity-associated tau spread compared with lower EA (estimate = 0.33; 95% CI, 0.003-0.67; P = .048). Aβ-targeting treatment appeared to mitigate plasma p-tau217-associated tau accumulation in patients with AD and higher EA (estimate = -0.52; 95% CI, -0.80 to -0.24; P < .001). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that higher EA was associated with faster tau accumulation and spread in Aβ+ individuals, highlighting the importance of Aβ clearance in mitigating tau progression in patients with AD and higher EA.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Cai Y, Fang L, Yang J, et al. Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease. JAMA Neurol. 2025. PMID: 40622710. doi:10.1001/jamaneurol.2025.1801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。